Chimeric antigen receptor (CAR)-T cell therapies have revolutionised treatment for hematological cancers; however, current ex vivo CAR-T cell therapies face logistical, manufacturing and clinical integration challenges. Emerging fast-manufacturing platforms offer promising clinical outcomes with reduced turnaround times, improved efficacay and safety, and potential for first-line treatment use.
This program aims to provide hematologists and oncologists with the latest data and discussion-based insights on emerging CAR-T cell therapies for high-risk LBCL and R/R DLBCL that aim to reduce the time of CAR-T cell therapy delivery, generating confidence for timely integration into clinical practice on approval.
Latest content
Latest content
Learning objectives
- Describe the challenges of traditional CAR-T cell therapies in hematological cancers such as LBCL and R/R DLBCL including time to treatment initiation, the need for bridging therapies and adverse event profiles
- Differentiate between traditional CAR-T cell therapy platforms and emerging platforms used for hematological cancers such as high-risk LBCL and R/R DLBCL based on differences in process, total turnaround time, T cell quality assurance and cost
- Recall the clinical trial evidence for CAR-T cell therapies in development for high-risk LBCL and R/R DLBCL delivered using novel delivery platforms in hematological cancers and the value of reducing time to CAR-T cell therapy initiation in high-risk patients
Learning objectives
- Describe the challenges of traditional CAR-T cell therapies in hematological cancers such as LBCL and R/R DLBCL including time to treatment initiation, the need for bridging therapies and adverse event profiles
- Differentiate between traditional CAR-T cell therapy platforms and emerging platforms used for hematological cancers such as high-risk LBCL and R/R DLBCL based on differences in process, total turnaround time, T cell quality assurance and cost
- Recall the clinical trial evidence for CAR-T cell therapies in development for high-risk LBCL and R/R DLBCL delivered using novel delivery platforms in hematological cancers and the value of reducing time to CAR-T cell therapy initiation in high-risk patients
Target audience
This program is aimed at specialist and community hematologists, oncologists and the wider healthcare team involved in treating patients with CAR-T therapies. This activity is for healthcare professionals outside of the USA and UK.
Planning committee
In addition to the expert faculty, Springer Health+ IME planners and staff include Rachel Goddard and Lucy Piper. The planning committee have no financial relationships to disclose.
All relevant financial relationships of the faculty have been mitigated.
Meet the faculty
Register for alerts
Complete the short registration form to be contacted when new learning content is made available, including ASH conference coverage, an “experts in conversation” webcast and free downloadable practice aid.
